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Abstract: The aim of this study is to investigate the effect of phase transition water-in-oil (w/o) 
microemulsions (ME) and liquid crystalline systems (LC) on the precorneal tear ﬁ lm (PCTF). The 
study used six albino NZ rabbits and monitored the integrity and stability of the PCTF before and 
after instillation of test formulations. The effects were evaluated by assessment of the PCTF lipid 
layer using interferometry, tear evaporation rate measurements, and indirect estimation of tear 
volume. Ocular application of test formulations changed the appearance of the PCTF lipid layer, 
indicating lipid layer disruption. The recovery time was longer in case of ME compared with an 
aqueous solution (SOL). The tear evaporation rate was increased after application of both ME 
and LC systems compared with the SOL, with the LC system showing the greatest effect. Tear 
volume measurement results revealed minimal changes associated with the instillation of both ME 
systems. Whilst phase transition w/o ME systems can interact with the PCTF lipid layer in albino 
New Zealand rabbits, their effect on the volume of resident tears was found to be minimal.
Keywords: ocular microemulsion; tear ﬁ lm; dry eye
Introduction
Topical application of drugs to the surface of the eye is the most common treatment 
modality for numerous ophthalmic disorders. However, only 5% of the applied drug 
in conventional eye drops penetrates the cornea/sclera and reaches intraocular tissues 
with the rest of the instilled dose undergoing transconjunctival systemic absorption 
or drainage via the nasolacrimal duct before transnasal or gastrointestinal absorption 
(Meseguer et al 1994; Lang 1995). Accordingly, one of the major challenges facing 
pharmaceutical formulators is to develop topical ocular delivery systems with improved 
ocular retention, increased corneal/scleral drug absorption and reduced systemic side 
effects whilst maintaining safety, simplicity and convenience. Many strategies have 
been adopted to partially or fully achieve such objective. These included the use of 
bioadhesive hydrogels (Durrani et al 1995), formulation of temperature or pH-sensitive 
in situ gel forming systems (Miller et al 1982; Gurny et al 1985), preparation of col-
lagen shields (Unterman et al 1988; Kaufman et al 1994), application of particulate 
and vesicular drug delivery systems such as nanoparticles, liposomes and niosomes 
(Fitzgerald, et al 1987; Calvo et al 1997; Vyas et al 1998; Pignatello et al 2002; Aggar-
wal and Kaur 2005) or employing micellar systems (Pepic ´ et al 2004).
Pseudoternary systems comprising sorbitan mono laurate (Crill 1), polyoxy-
ethylene 20 sorbitan mono-oleate (Crillet 4), ethyl oleate (Crodamol EO) and 
water can give rise to at least two colloidal microstructures, namely, water-in-oil 
microemulsions (w/o ME) and lamellar liquid crystalline systems (LC) as well 
as an oil-in-water coarse emulsion (EM) (Alany et al 2001). These w/o ME 
are attractive as vehicles for topical ocular drug delivery. They offer several 
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advantages such thermodynamic stability, ability to accom-
modate drugs with low water solubility, ease of application 
and possible penetration enhancing effect due to their 
nonionic surfactant content (Lang 1995). Moreover, and 
upon phase transition of selected w/o ME systems due to 
aqueous dilution, the resultant LC system were previously 
shown to display the desirable high viscosity and psuedo-
plasticity. Such LC systems are viscous enough to promote 
precorneal retention, yet can thin and display less resistance 
upon blinking. Such formulations are therefore expected to 
perform better than traditional viscous formulations (Alany 
et al 2001). We have previously shown that selected col-
loidal systems (ME 5%, ME 10%, and LC) can prolong the 
precorneal retention and improve the ocular bioavailability 
of the model hydrophilic drug, pilocarpine hydrochloride 
(Alany et al 2006). In addition, we have recently shown 
that these systems can prolong the release of pilocarpine 
hydrochloride in vitro with extended duration of action in 
vivo (Chan et al 2007). Furthermore, we have shown that 
these surfactant-containing systems were practically nonir-
ritant to the eye according to the results obtained using a 
modiﬁ ed HET-CAM test (Alany et al 2006). However, it 
should be emphasized that the HET-CAM is a model for 
the conjunctiva (Leighton et al 1985). It follows that the 
previously generated ocular irritation data (Alany et al 
2006) did not consider any potential interactions with and 
destabilizing effects on the precorneal tear ﬁ lm (PCTF) 
which is one of the principal defense mechanisms of the 
eye, hence the need to address that.
The PCTF, is a delicate layer that maintains ocular 
hydration and ensures a smooth optical refracting surface. 
It lubricates the corneal epithelium and the constant turn-
over of tears allows for the effective removal of irritants. 
Furthermore, the tears contain antimicrobial defences, such 
as immunoglobulins, lysozymes, and white blood cells, 
which help protects the eye from potential infections (Terry 
2001). The PCTF comprises three layers (Figure 1). The 
innermost part is composed mainly of glycoproteins and is of 
importance for wetting the corneal and conjuntival epithelia 
as well as promoting the stability of the watery tear ﬁ lm (Vale 
and Cox 1985; Terry 2001). The central layer is aqueous in 
nature and is produced by the main and accessory lacrimal 
glands; and the outermost layer of the PCTF is a thin lipid 
layer, produced by 20–30 meibomian glands located in the 
tarsal plates of the rabbit eye lids. Disruption of this lipid 
layer leads to exposure and subsequent evaporation of the 
underlying aqueous tears, causing an evaporative dry eye. 
This is a potentially serious manifestation associated with 
debilitating symptoms and without appropriate treatment 
predisposes the patient to ocular surface damage.
The primary objective of this study was to evaluate the 
effect of selected colloidal systems (ME 5%, ME 10%, and 
LC) on the PCTF in rabbits. It investigated the effect of these 
systems on the outer lipid layer of the PCTF with the aqueous 
solution formulation (SOL) being used as the control. The 
study was conducted on albino NZ rabbits and monitored 
three aspects, these are:
• Interferometric assessment of the lipid layer integrity,
• Measurement of the tear evaporation rate and;
• Indirect estimation of tear volume.
Materials and methods
Materials
Ethyl oleate (Crodamol EO), sorbitan mono laurate (Crill 1) 
and polyoxyethylene (20) sorbitan mono-oleate (Crillet 
4 super) were obtained form BTB Oleochemicals 
(Auckland, New Zealand). Pilocarpine hydrochloride 
(PHCl) USP grade was obtained from Sigma Chemical 
Co. (St. Louis, USA). Deionised water was used as the 
aqueous component.
Preparation of ocular formulations
Table 1 outlines the composition of the tested ocular 
formulations. The formulations contained the two nonionic 
surfactants (Crill 1 and Crill 4, blended at 2:3 weight ratio) 
with ethyl oleate (Crodamol EO) as the oil component. The 
formulations were prepared at a constant surfactant blend/oil 
weight ratio (3:2). These formulations were characterized as 
two W/O ME formulations containing an aqueous component 
at 5% and 10% w/w (ME 5% and ME 10%), respectively 
with the later being close to the W/O ME–LC phase bound-
ary. The other formulations were an LC formulation with 
an aqueous component at 26% w/w, an O/W EM system 
with 85% w/w aqueous and an aqueous solution (SOL). 
Table 1 Composition of the investigated formulations
Formulation Composition (weight ratios)
ME 5% PHCl, Water, Crill1, Crillet 4, Crodamol EO (1:4:22.8:
 34.2:38)
ME 10% PHCl, Water, Crill1, Crillet 4, Crodamol EO (1: 9:21.6:
 32.4:36)
LC PHCl, Water, Crill1, Crillet 4, Crodamol EO (1: 25:17.8:
 26.6:29.6)
EM PHCl, Water, Crill1, Crillet 4, Crodamol EO (1:84:3.6:
 5.4:6)
SOL PHCl,  Water (1:99)
Abbreviations: ME, W/O microemulsion; LC, lamellar liquid crystalline system; EM, 
O/W coarse emulsion; SOL, aqueous solution; PHCl, pilocarpine hydrochloride.
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The model hydrophilic drug was incorporated by replacing 
the water content with an aqueous solution containing drug 
sufﬁ cient to produce a constant concentration (1% w/w) in 
all formulations. The oil, surfactant blend and the aqueous 
phase were vortex mixed for 10 minutes and the result-
ing systems were left to equilibrate overnight at ambient 
temperature before conducting the in vivo evaluation. The 
detailed formulation method and phase behavior for these 
systems has been previously described (Chan et al 2007). 
The ﬂ ow properties and the viscosity of the formulations 
were determined using a DV III cone and plate Brookﬁ eld 
viscometer, ﬁ tted with a CP 52 spindle and operated using a 
Rheocalc programme (Brookﬁ eld Engineering Laboratories 
Inc., Stoughton, MA, USA).
Application of the test formulations
The studies were conducted using six New Zealand albino 
rabbits weighing between 2 and 3 kg each. The rabbits were 
Key:
a
b
Thick non-polar hydrophobic lipids such as wax esters and sterol esters. 
Thin polar lipid phase containing hydrophilic polar lipids such as phospholipids
Metabolites such as glucose and urea
Electrolytes such as sodium, potassium, magnesium, calcium, chloride, bicarbonate,
phosphate and hydrogen ions.
Proteins including tear lipocalin, albumin, antibodies, lysozyme, beta-lysin, lactoferrin, lactate 
dehydrogenase, pyruvate kinase, malate dehydrogenase and amylase.
Soluble mucins 
Membrane Mucins
Glycocalyx is a fine layer of glycoproteins covering the ocular surface 
Figure 1 Schematic illustration of the precorneal tear fi lm (PCTF) outlining comprising layers (Not to scale).
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fed a normal diet and exposed to alternating 12 hours light 
and dark cycles. The rabbits were kept in restraining cages 
with adequate space for movement throughout the course of 
the experiment. All experiments were performed in the same 
room under the same air conditioning and standard lighting 
conditions; light intensities were monitored using a pho-
tometer (Lux Meter Q-1400, DSE). The same rabbits were 
used to evaluate all formulations with at least 48 hours wash 
out period between each application. Each test formulation 
(20 µL) was instilled into the lower fornix of the conjunctival 
sac of the left eye using a positive displacement pipette with 
the right eye serving as a control.
All animal manipulations were conducted in accordance 
with the guidelines of The University of Auckland Animal 
Ethics Committee.
Lipid layer thin f ilm interferometery
The lipid layer quality and an estimate of lipid layer thick-
ness were determined using a Keeler TearscopeTM (Keeler 
Ltd, Berkshire, UK). The TearscopeTM is equipped with a 
diffuse cold cathode lamp and is used in conjunction with a 
hand held nonilluminated biomicroscope (Haag-Streit Bern, 
Switzerland, 16× magniﬁ cation) to provide an interferomet-
ric assessment of the lipid layer. The light generated by the 
TearscopeTM is reﬂ ected from the surface of the lipid layer 
and from the interface between that lipid and aqueous layers 
of the tear ﬁ lm producing various interference patterns (Yokoi 
and Komuro 2004). Where the lipid layer is approximately 
100–140nm (approximately 1/4 of the wavelength of vis-
ible light), coloured fringes become visible. At thicknesses 
below this, the colour patterns disappear and there is an 
apparent loss of lipid layer structure. This apparent loss of 
structure or so-called “disruption” occurs when a drop of a 
conventional eye drop or any other ocular dosage forms is 
instilled into the eye.
Figure 2 shows the appearance of both an intact and 
disrupted PCTF lipid layer. The lipid layer quality and thick-
ness was assessed immediately before application of the test 
formulation. This assessment provided the baseline coloured 
fringe pattern for each rabbit. Immediately after instillation 
of the test formulation the tear ﬁ lm lipid layer was monitored 
and the time taken for the lipid layer to resume its baseline 
pattern was recorded. This time was taken as a measure of 
the degree of disruption of the PCTF lipid layer.
Lipid layer integrity (Evaporimetry)
Disruption of the PCTF lipid layer can cause an increased 
evaporation of the underlying aqueous layer which can 
lead to an evaporative dry eye. Accordingly, the tear 
evaporation rate (ﬂ ux) was taken as an indirect, but objec-
tive measure of the stability of the precorneal tear ﬁ lm. 
These measurements were carried out using a Servomed 
Evaporimeter, model EP3 (Servomed, Varberg, Sweden). 
This Evaporimeter has two sensors, located a known 
distance a part (1 cm) and held at a known distance (1.5 
cm) from the evaporating surface (the eye) to measure 
the vapour pressure gradient, which is proportional to the 
evaporation rate.
Before instillation of the test formulations, three con-
secutive baseline readings were obtained. The procedure 
was conducted by placing the probe at a distance of 1.5 cm 
from the surface of the eye with a modiﬁ ed swimming 
goggle mounted to the probe. This modiﬁ cation prevents 
the probe from touching the ocular surface, which may 
damage the sensors and irritate the eye. The goggle was 
placed over the left eye of the rabbit for a period of 120 
seconds. After allowing 60 seconds for stabilization, mea-
surements were taken only from 60–120 seconds (Craig 
and Blades 1997). After establishment of the baseline 
measurement, 20 µl of the test formulation was instilled 
into the lower conjunctival sac of the rabbit’s left eye. 
The initial evaporation rate was measured one and a half 
minutes after instillation, and readings were taken every 
15 minutes, until three consecutive baseline readings 
were recorded.
The recorded evaporation rates were plotted as a function 
of time. The area under the tear evaporation rate versus time 
curve (AUC) was calculated for the individual formulations 
using the trapezoidal method.
Tear volume measurements (Phenol Red 
thread test)
Indirect tear volume measurements were conducted by 
inserting a phenol red impregnated thread (Zone-Quick, 
Menicon Co. Ltd, Nagoya, Japan) into the inferior fornix 
of the conjunctival sac (Figure 3). The pH sensitive thread 
soaks up the tear ﬂ uid, changes from yellow to red on con-
tact with tears and the wetted length is measured after 15 
seconds (Figure 3). Less than 10 mm of thread wetting in 
15 seconds is considered to be indicative of tear deﬁ ciency 
in humans.
To establish baseline tear volume, the thread was placed 
into the inferior fornix of the conjunctival sac of the left 
eye of the rabbit for 15 seconds, after which the length of 
the tear wetted portion was measured (Craig and Blades 
1997). The test formulation (20 µl) was then instilled into 
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the lower fornix of the conjunctival sac of the same eye, and 
a second phenol red thread test was conducted ﬁ ve minutes 
post-instillation to assess the tear volume changes. The dif-
ference between the measured wetted length after and before 
instillation was recorded and taken as an indirect measure 
for the tear volume. The volume of the resident tears in the 
precorneal area is directly proportional to the wetting length 
of the phenol red thread.
Statistical analysis
A two-way analysis of variance (ANOVA) was used to deter-
mine the overall statistically signiﬁ cant difference between 
the formulations and biological differences between the ani-
mals. After excluding any animal effect due to insigniﬁ cant 
differences between the six rabbits, a one-way ANOVA fol-
lowed by Tukey’s pairwise comparisons at a 95% conﬁ dence 
interval was used to test for signiﬁ cant difference between 
formulations. The two-way, one-way ANOVA and Tukey’s 
pairwise comparisons were performed using Minitab™ sta-
tistical analysis programme Release 12.
Results
The quality and stability of the PCTF lipid layer was moni-
tored before and after instillation of the phase transition 
formulations using the TearscopeTM. As expected, the initial 
observations conducted (before instillation of the test for-
mulations) showed an intact lipid layer as indicated by the 
normal coloured fringe patterns (Figure 2a). This was the case 
with all rabbits. After application of the test formulations, the 
appearance of the lipid layer changed from its normal (Figure 
2a) to the disrupted appearance (Figure 2b), indicating a 
degree of lipid layer perturbation and disruption. To com-
pare the test formulations, the time taken for the lipid layer 
to return to its baseline level was determined and the results 
are presented in Table 2. Statistical analysis using the two-
way ANOVA revealed no signiﬁ cant differences between 
rabbits (p  0.05). On the other hand Tukey’s pairwise 
comparison indicated signiﬁ cant differences between the 
SOL and all other formulations (p  0.05) but no signiﬁ cant 
differences between ME 5%, ME 10%, LC and the coarse 
emulsion EM (p  0.05). The solution formulation (SOL) 
showed a signiﬁ cantly faster recovery of the lipid layer to 
(a)
(b)
Figure 2 The appearance of the precorneal tear fi lm lipid layer, (a) intact and (b) 
disrupted.
Figure 3 The Phenol Red thread test. Note the dark and bright discoloration of the 
thread indicating wet and dry portions respectively.
Table 2 Time required by the lipid layer to return to its baseline 
pattern as measured by the TearscopeTM after instillation of the 
test formulations. Results are presented as mean ± SD, N = 6
Formulation Average recovery time (seconds)
ME 5% 271.7 ± 29.3
ME 10% 281.7 ± 26.5
LC 395.0 ± 41.1
EM 255.7 ± 22.9
SOL 117.5 ± 12.6*
Note: *Signifi cantly different from all the other formulation (p  0.05).
Clinical Ophthalmology 2008:2(1)134
Chan et al
its baseline state; while the liquid crystalline system (LC) 
demonstrated the greatest interaction with the lipid layer 
with the recovery time period (395 seconds), being longer 
than all other formulations (Table 2). A similar result was 
recorded for the two microemulsion systems (ME 5% and 
ME 10%), with average recovery times of 271.7 seconds and 
281.7 seconds, respectively. This was also comparable to the 
lipid layer recovery time generated by the coarse emulsion 
(EM), being 255.7 seconds.
The tear evaporation rate (ﬂ ux) was measured as the 
second parameter in relation to the potential interaction 
of these test colloidal systems with the PCTF. The rate of 
tear evaporation was measured as a function of time after 
instillation of the test formulations. The results are shown 
in Figure 4. It is evident that all three colloidal systems 
(ME 5%, ME 10%, and LC) had a pronounced effect on 
the tear evaporation rate. On the other hand the coarse 
emulsion EM demonstrated a less pronounced effect, 
where as SOL exhibited a minimal effect (Figure 4). For 
objectively comparing the different formulations with 
respect to their effect on the extent of tear evaporation and 
the duration of tear evaporation, the area under the tear 
evaporation rate versus time curve (AUC) was calculated. 
The results are presented is Table 3. The liquid crystalline 
formulation (LC) produced the highest tear evaporation rate 
as reﬂ ected by an AUC of 10.65 g. m−2, followed by the 
two microemulsion systems with AUC values of 8.15 g. m−2 
and 6.2 g. m−2 for ME 5% and ME 10%, respectively. The 
coarse emulsion formulation (EM) resulted in an AUC value 
of 4.05 g. m−2, whilst the SOL produced a minimal effect 
on tear evaporation as reﬂ ected by the AUC (0.40 g. m−2). 
The statistical analysis revealed signiﬁ cant differences 
(p  0.05) between both phase transition formulations 
(ME 5% and ME 10%) and the solution formulation (SOL). 
Furthermore, the LC formulation produced a signiﬁ cantly 
higher AUC (p  0.05) compared to the EM and SOL 
formulations but was not signiﬁ cantly different from both 
ME formulations (p  0.05).
The volume of tears was indirectly measured as the third 
parameter reﬂ ecting the effect of the test formulations on 
the stability and integrity of the PCTF lipid layer. This was 
determined using the Phenol Red impregnated thread. The 
results were calculated as the difference in the length of 
the wetted portion of the thread measured after and before 
instillation of the formulations. The results are presented 
in Table 4. The largest change was apparent with the LC 
formulation followed by the coarse emulsion (EM) then the 
solution (SOL) with both phase-transition microemulsion 
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Figure 4 The tear evaporation rate, measured using a Servomed Evaporimeter. Data were recorded at different time points after instillation of different formulations. 
Results are presented as mean ± SD, N = 6.
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formulations (ME 5% and ME 10%) producing the smallest 
effect on tear volume as indicated by the smallest difference 
in the length of the wetted thread (Table 4).
Discussion
Initial TearscopeTM examination of the rabbit eye revealed 
consistent appearance of the PCTF lipid layer for all rabbits. 
This indicated that the study employed rabbits with healthy 
eyes. Shortly after instillation of the individual formulations 
the appearance of the lipid layer began to change from the 
normal to the disrupted appearance (Figure 2b). Calculat-
ing the time needed for the lipid layer to recover its normal 
appearance, the solution (SOL) required the shortest. On the 
other hand, the coarse emulsion (EM) as well as both ME 
formulations required signiﬁ cantly longer time compared 
with the solution (SOL), with the LC system recording the 
longest time amongst all tested formulations. The importance 
of the lipid layer for the stability of the PCTF was previ-
ously reported. The major function of the lipid layer is to 
prevent the evaporation of tears with a disrupted lipid layer 
being associated with the well-known evaporative dry eye 
syndrome (Craig and Tomlinson 1997; Johnson and Murphy 
2004). Accordingly, the evaporation rate of the tears was 
monitored before and after instillation of the tested formu-
lation. As with the TearscopeTM results, the solution (SOL) 
yielded the lowest evaporation rate, whereas the LC system 
displayed the highest evaporation rate. It should be noted 
that the higher rates of evaporation obtained after recovery 
of the lipid layer is indeed unexpected. This may indicate a 
possible increased tear production and/or ﬂ ow post formula-
tion instillation.
The physicochemical model of the lipid layer of the 
PCTF has revealed a relatively thick outer layer comprising 
nonpolar lipids with a thinner polar inner layer comprising 
phospholipids (McCulley and Shine 1997). Such a structure is 
most likely to be destabilised by any formulation containing 
surfactants. Accordingly, the surfactant content of individual 
formulation was compared with the AUC values (Table 3). 
The rank of the AUC did not relate with the surfactant con-
tent for the individual formulations. According to Table 3, 
the LC formulation which has an intermediate amount of 
surfactant produced the highest AUC and evaporation rate. 
This may indicate that the surfactant concentration is not the 
main variable affecting the stability of the lipid layer. Previ-
ous investigations on these systems revealed similar surface 
tension values for all the ME formulations and concluded 
that these formulations are in the reverse micellar state 
(Chan et al 2007). This indicates that the concentration of 
the surfactant blend was above the critical micelle concen-
tration in all cases. This explains the more powerful effect 
of the colloidal formulations compared with the solution 
formulation (SOL).
Previous rheological investigations of the test formula-
tions revealed a dependence of the viscosity on the water 
content with the viscosity increasing with increasing the 
water content, reaching its maximum with LC formula-
tion and dropping back to values close to the minimum 
in case of the EM (Table 3) (Alany et al 2001). More 
viscous formulations can promote longer ocular retention 
which has been previously reported for these formulations 
(Alany et al 2006; Chan et al 2007). This can explain the 
more pronounced effect of the LC system on the PCTF 
lipid layer. The rheological behaviour and viscosity for 
the formulations under investigation have been previously 
reported (Alany et al 2001; Chan et al 2007) and are pre-
sented in Table 3.
Table 3 The area under the evaporation rate versus time curve (AUC) presented as mean values ± SD, N = 6 in relation to 
surfactant content and viscosity of the test formulations
Formulation AUC (g m−2) Surfactant content (%w/w) Type of fl ow Viscosity (mPa s)
ME 5% 8.15 ± 1.75* 57.0 Newtonian 112
ME 10% 6.20 ± 1.28* 54.0 Newtonian 167
LC 10.65 ± 2.22** 44.4 Non-Newtonian* * * 5487
EM 4.05 ± 1.32 9.0 Newtonian 4.17
SOL 0.40 ± 0.15 0 Newtonian 1.1
Notes: *Signifi cantly different from SOL (p  0.05); **Signifi cantly different from EM and SOL (p  0.05); ***Type of fl ow is non-Newtonian pseudoplastic.
Table 4 The difference in the wetted length of the Phenol Red 
thread calculated from post-instillation minus pre-instillation 
length. Results presented as mean ± SD, N = 6
Formulation Average Difference (mm)
ME 5% 4.67 ± 2.33
ME 10% 4.17 ± 2.22
LC 11.33 ± 5.19
EM 8.33 ± 3.89
SOL 6.33 ± 3.47
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The Phenol Red thread test was used to indirectly mea-
sure the tear volume, with the results being calculated as 
post-instillation minus pre-instillation wetted length. The 
test provided unexpected results which did not relate well 
to those obtained from either the interferometric evaluation 
or the tear evaporation measurement. Surprisingly both ME 
systems displayed the least difference on average. It has 
been previously proposed that the Phenol Red thread test 
measures uptake of a (small) amount of ﬂ uid residing in the 
eye, stimulates a low degree of reﬂ ex tearing, and reﬂ ects 
the absorption characteristics of the thread dependent on the 
biophysics or composition of tears (Tomlinson et al 2001). 
Our results can be explained by the tendency of both ME 
systems to absorb water by passive diffusion from the sur-
rounding environment (tear ﬂ uid). This is mainly due to their 
relatively low water content and the resultant concentration 
gradient that acts as the driving force for the water mass 
transfer process from the surrounding environment into the 
ME formulation. It should be noted that despite the current 
ﬁ ndings, these formulation were previously reported to be 
well tolerated by the eye, based on irritation test using the 
HET-CAM model (Alany et al 2006). However, it should be 
noted that the HET-CAM model represents the conjunctiva 
with no direct relation to the PCTF (Leighton et al 1985). It 
is encouraging to note that none of these systems induced any 
visible signs of irritation or discomfort when instilled into the 
eye of albino New Zealand rabbits (Chan et al 2007).
Moreover, it is interesting to report that some undesir-
able effects have been reported, even for a conventional eye 
ointment, which is a commonly used formulation to promote 
prolonged ocular retention. It has been previously reported 
that due to the disruption of the PCTF-optical interface, 
an eye ointment produced local side effects such as visual 
disturbances and foreign body sensation, although in most 
cases these were self-limited and well tolerated by patients 
(MacKeen 1980; Frangie 1985; Leighton et al 1985). It has 
also been reported that all eye ointments and oils interact 
with and destabilize the PCTF, and as such increase the 
risks of acute dry eye upon application (Norn and Opauszki 
1977). This was further conﬁ rmed by the study conducted 
by Tsubota and colleagues (1999), where they investigated 
a calcium-containing ointment for the treatment of dry eye. 
Patients experienced increased blinking rates, tear evapora-
tion and increased tear break up time upon application of the 
ointment. In another study that compared a hydro-gel and 
a vitamin A based ointment, results showed that while no 
signiﬁ cant differences were found in the aspects of ocular 
burning, eye dryness and itching sensations between the 
two formulations, the incidence of visual disturbance and 
adherent eyelashes were much higher in patients using the 
ointment (Smolle et al 2004).
Conversely, it has been recently shown that the topical 
ocular application of a lipid emulsion eye drop increases the 
PCTF lipid layer thickness and beneﬁ t patients with deﬁ -
cient lipid layers experiencing dry eye symptoms (Scafﬁ di 
and Korb 2007). Furthermore, there is increasing evidence 
that lipid based colloidal systems such as liposomes are 
superior to conventional aqueous solutions in reversing the 
undesirable symptoms associated with dry eye (Peters et al 
2003). Systems based on phosphatidylcholine and phospha-
tidylinositol were shown to initially destabilize the PCTF 
lipid layer more than aqueous solutions (Peters et al 2003). 
Nevertheless, a liposome eye spray based on phosphatidyl-
choline and the cationic surfactant benzyl dimethylstearyl 
ammonium chloride showed signiﬁ cant improvement in vari-
ous dry eye clinical parameters compared with an aqueous 
solution (Lee et al 2004). Feedback from patients revealed 
that the liposome eye spray resulted in improvement of dry 
eye symptoms in 72% of the cases, despite an initial burn-
ing sensation post application (Lee et al 2004). This spray is 
commercially available for dry eye patients under the trade 
names Clarymist™ and Tears Again™.
Conclusion
Selected phase transition w/o ME systems can interact with 
and destabilize the PCTF lipid layer in albino New Zealand 
rabbits. However, their effect on the volume of resident 
tears was found to be minimal. Although the presence 
of a surfactant in an ocular formulation can play a major 
role in producing undesirable effects, the viscosity of the 
formulation must also be carefully considered as it may be 
a signiﬁ cant determining factor in many cases. Despite the 
desirable rheological properties and prolonged ocular reten-
tion of phase transition w/o ME systems, there may still be 
issues around their compatibility with the PCTF that warrants 
further investigation.
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